Tuberculosis Therapeutics Global Market Report 2025

Description

Tuberculosis therapeutics encompass pharmaceutical treatments aimed at preventing and curing tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. These treatments focus on eradicating the bacteria, reducing transmission, and improving outcomes for patients, particularly those with drug-resistant strains.

The primary types of tuberculosis therapeutics are active tuberculosis (TB) and latent tuberculosis (TB). Active tuberculosis is a contagious bacterial infection that primarily affects the lungs, leading to symptoms such as persistent cough, fever, and weight loss. Available product types include isoniazid, rifampin, pyrazinamide, hydrazine derivatives, miscellaneous anti-tubercular drugs, and ethambutol. The treatments are administered via various routes, such as oral, parenteral, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The tuberculosis therapeutics market research report is one of a series of new reports from The Business Research Company that provides tuberculosis therapeutics market statistics, including the tuberculosis therapeutics industry global market size, regional shares, competitors with the tuberculosis therapeutics market share, detailed tuberculosis therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the tuberculosis therapeutics industry. This tuberculosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tuberculosis therapeutics market size has grown strongly in recent years. It will grow from $1.88 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 6.58%. The growth during the historical period can be attributed to the increasing incidence of tuberculosis, the rising adoption of tuberculosis therapeutics, greater awareness of tuberculosis (TB), the growing prevalence of XDR-TB, and the increasing cases of drug-resistant tuberculosis.

The tuberculosis therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.32%. The anticipated growth in the forecast period is driven by increased investments in healthcare infrastructure, heightened awareness and education efforts, greater investment in research and development, an increase in product approvals for various anti-TB agents, expanded research funding, and a growing geriatric population. Key trends expected during this period include advancements in drug development, the rise of personalized medicine, combination therapies, integration of digital health solutions, and the use of AI and machine learning in drug discovery.

The increasing rates of TB-HIV co-infections are expected to drive the growth of the tuberculosis therapeutics market in the coming years. TB-HIV co-infection refers to individuals simultaneously infected with tuberculosis (TB) and human immunodeficiency virus (HIV). The rise in co-infections is attributed to the immune system suppression caused by HIV, which increases susceptibility to TB, along with the global overlap of these epidemics in high-risk populations. Tuberculosis therapeutics play a crucial role in addressing these co-infections by providing targeted treatments that combat TB while mitigating HIV-related immune suppression, thereby improving patient outcomes and alleviating the dual disease burden. For example, in October 2023, data from gov.uk indicated that England recorded 3,805 new HIV diagnoses in 2022, reflecting a 22% increase from the 3,118 cases reported in 2021. Such rising co-infection rates are significantly fueling the demand for tuberculosis therapeutics.

Leading companies in the tuberculosis therapeutics market are focusing on advancements such as combination therapies to enhance treatment effectiveness, shorten therapy durations, and address drug-resistant tuberculosis strains. Combination therapy utilizes two or more drugs from different classes to boost treatment efficacy, minimize resistance, and improve overall patient outcomes. For instance, in July 2024, Johnson & Johnson achieved a breakthrough with the approval of SIRTURO (bedaquiline) by the U.S. FDA and the European Commission. SIRTURO is the first drug in over 40 years specifically designed for multidrug-resistant tuberculosis (MDR-TB). By targeting the ATP synthase enzyme critical for TB bacteria's energy production, SIRTURO offers a targeted and potent treatment option. When incorporated into combination therapies, it enhances regimen efficacy, reduces treatment timelines, and promotes better patient adherence.

In May 2024, BioVersys AG, a Swiss biotechnology company, entered into a strategic partnership with GSK plc to accelerate the clinical development of alpibectir (BVL-GSK098) for tuberculosis treatment. This collaboration aims to advance innovative therapeutic solutions for TB. GSK plc, a UK-based pharmaceutical company, is known for its contributions to developing and manufacturing groundbreaking medicines, including treatments for tuberculosis.

Major players in the tuberculosis therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Macleods Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., Sequella Inc.

North America was the largest region in the tuberculosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tuberculosis therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tuberculosis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tuberculosis therapeutics market consists of sales of combination therapies, vaccines, supportive therapies, biologics, and newer drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tuberculosis Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tuberculosis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tuberculosis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tuberculosis therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Active Tuberculosis (TB); Latent Tuberculosis (TB)
2) By Product Type: Isoniazid; Rifampin; Pyrazinamide; Hydrazine derivatives; Miscellaneous anti-tubercular drugs; Ethambutol
3) By Route of Administration: Oral; Parenteral; Other route of administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol); Second-Line Drugs (Fluoroquinolones, Aminoglycosides); Combination Therapies; Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis; Rifampicin-Based Regimens; Rifapentine-Based Regimens; Combination Prophylactic Therapies
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33913

1. Executive Summary

2. Tuberculosis Therapeutics Market Characteristics

3. Tuberculosis Therapeutics Market Trends And Strategies

4. Tuberculosis Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Tuberculosis Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Tuberculosis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Tuberculosis Therapeutics Market Growth Rate Analysis
5.4. Global Tuberculosis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Tuberculosis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Tuberculosis Therapeutics Total Addressable Market (TAM)

6. Tuberculosis Therapeutics Market Segmentation

6.1. Global Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Active Tuberculosis (TB)
Latent Tuberculosis (TB)
6.2. Global Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Isoniazid
Rifampin
Pyrazinamide
Hydrazine Derivatives
Miscellaneous Anti-Tubercular Drugs
Ethambutol
6.3. Global Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Route of Administration
6.4. Global Tuberculosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other Distribution Channels
6.5. Global Tuberculosis Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Ambulatory Surgical Centers
Other End-Users
6.6. Global Tuberculosis Therapeutics Market, Sub-Segmentation Of Active Tuberculosis (TB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)
Second-Line Drugs (Fluoroquinolones, Aminoglycosides)
Combination Therapies
Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
6.7. Global Tuberculosis Therapeutics Market, Sub-Segmentation Of Latent Tuberculosis (TB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Isoniazid Prophylaxis
Rifampicin-Based Regimens
Rifapentine-Based Regimens
Combination Prophylactic Therapies

7. Tuberculosis Therapeutics Market Regional And Country Analysis

7.1. Global Tuberculosis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Tuberculosis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tuberculosis Therapeutics Market

8.1. Asia-Pacific Tuberculosis Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tuberculosis Therapeutics Market

9.1. China Tuberculosis Therapeutics Market Overview
9.2. China Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tuberculosis Therapeutics Market

10.1. India Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tuberculosis Therapeutics Market

11.1. Japan Tuberculosis Therapeutics Market Overview
11.2. Japan Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tuberculosis Therapeutics Market

12.1. Australia Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tuberculosis Therapeutics Market

13.1. Indonesia Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tuberculosis Therapeutics Market

14.1. South Korea Tuberculosis Therapeutics Market Overview
14.2. South Korea Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tuberculosis Therapeutics Market

15.1. Western Europe Tuberculosis Therapeutics Market Overview
15.2. Western Europe Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tuberculosis Therapeutics Market

16.1. UK Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tuberculosis Therapeutics Market

17.1. Germany Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tuberculosis Therapeutics Market

18.1. France Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tuberculosis Therapeutics Market

19.1. Italy Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tuberculosis Therapeutics Market

20.1. Spain Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tuberculosis Therapeutics Market

21.1. Eastern Europe Tuberculosis Therapeutics Market Overview
21.2. Eastern Europe Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tuberculosis Therapeutics Market

22.1. Russia Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tuberculosis Therapeutics Market

23.1. North America Tuberculosis Therapeutics Market Overview
23.2. North America Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tuberculosis Therapeutics Market

24.1. USA Tuberculosis Therapeutics Market Overview
24.2. USA Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tuberculosis Therapeutics Market

25.1. Canada Tuberculosis Therapeutics Market Overview
25.2. Canada Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tuberculosis Therapeutics Market

26.1. South America Tuberculosis Therapeutics Market Overview
26.2. South America Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tuberculosis Therapeutics Market

27.1. Brazil Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tuberculosis Therapeutics Market

28.1. Middle East Tuberculosis Therapeutics Market Overview
28.2. Middle East Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tuberculosis Therapeutics Market

29.1. Africa Tuberculosis Therapeutics Market Overview
29.2. Africa Tuberculosis Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Tuberculosis Therapeutics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Tuberculosis Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tuberculosis Therapeutics Market Competitive Landscape And Company Profiles

30.1. Tuberculosis Therapeutics Market Competitive Landscape
30.2. Tuberculosis Therapeutics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Tuberculosis Therapeutics Market Other Major And Innovative Companies

31.1. Bayer AG
31.2. Sanofi S.A.
31.3. Novartis AG
31.4. GlaxoSmithKline plc
31.5. Viatris Inc.
31.6. Teva Pharmaceutical Industries Ltd.
31.7. Astellas Pharma Inc.
31.8. Macleods Pharmaceuticals Ltd.
31.9. Cipla Limited
31.10. Hikma Pharmaceuticals plc
31.11. Lupin Limited
31.12. Alkem Laboratories Limited
31.13. Emcure Pharmaceuticals Limited
31.14. Otsuka Pharmaceutical Co. Ltd.
31.15. Sequella Inc.

32. Global Tuberculosis Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tuberculosis Therapeutics Market

34. Recent Developments In The Tuberculosis Therapeutics Market

35. Tuberculosis Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Tuberculosis Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Tuberculosis Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Tuberculosis Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer